Study on Biomarkers in AML Patients Post-Stem Cell Transplantation with Menin Inhibition
The study focuses on biomarkers in AML patients who have relapsed post-allogeneic stem cell transplantation and are treated with menin inhibitors.
Therapeutic Area
Therapeutic area intelligence for Acute Myeloid Leukemia with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
A Phase 1 trial for tomivosertib in relapsed or refractory acute myeloid leukemia is set to begin, utilizing Bayesian optimal interval dose finding design.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.